Grant: Alliance Grants
University of Guelph
$43,335.00
Development of a high-yield and high-purity isolation kit for extracting extracellular vesicles from complex biological samples
FY 2022-23
Summary
The proposed research project includes a partnership between the BioMed Innovation (BMI) laboratory (Dr. Li) at the University of Guelph (UofG, Guelph, Ontario) and Galenvs Sciences Inc. (Montreal, Quebec). The primary goal of the collaborative research partnership is to develop an EV isolation kit to isolate and purify extracellular vesicles (EVs) from complex biological fluids (e.g., blood plasma/serum, urine) with high yield and high purity. EVs are nanoscale vesicles secreted from cells into body fluids such as blood and urine. Since EVs carry biomolecules similar to their cells of origin, analysis of EV contents in biofluids has been a promising tool for disease diagnosis and treatment monitoring. EVs (specifically, exosomes) also have the capacity to serve as a therapeutic platform to treat complex diseases, with low immunogenicity and tumorigenicity. However, EV isolation from biofluids constitutes a major bottleneck in these applications largely due to the yield and purity limitations of the current technologies. This project aims to overcome these challenges by developing an aptamer-functionalized-magnetic-nanoparticle-based extraction kit with easy-to-follow protocols and ready-to-use reagents for isolating EVs from various types of biofluids, with high yield and purity, suitable for downstream EV molecular analysis. Successful completion of this project has a substantial economic impact on the biotech industry of Canada. The potential outcomes and impacts include: (1) one of the first EV isolation kits made in Canada with both established protocols and ready-to-use reagents; (2) enabling broader applications of EVs in health and life sciences; (3) enhancing the competitiveness of the Canadian biotechnology companies both at home and in the global market; (4) training of HQP in nano-biotechnology and EV science.
Program
Alliance Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
566522-2021
Name nom
Li, Huiyan H
Department département
Engineering, School of
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2021
Award amount
43335
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5400
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Biochemistry
Research subject fr
Biochimie
Installment
inst:2
Partie
1
Nb partie
2
Application title
Development of a high-yield and high-purity isolation kit for extracting extracellular vesicles from complex biological samples
Application summary
The proposed research project includes a partnership between the BioMed Innovation (BMI) laboratory (Dr. Li) at the University of Guelph (UofG, Guelph, Ontario) and Galenvs Sciences Inc. (Montreal, Quebec). The primary goal of the collaborative research partnership is to develop an EV isolation kit to isolate and purify extracellular vesicles (EVs) from complex biological fluids (e.g., blood plasma/serum, urine) with high yield and high purity. EVs are nanoscale vesicles secreted from cells into body fluids such as blood and urine. Since EVs carry biomolecules similar to their cells of origin, analysis of EV contents in biofluids has been a promising tool for disease diagnosis and treatment monitoring. EVs (specifically, exosomes) also have the capacity to serve as a therapeutic platform to treat complex diseases, with low immunogenicity and tumorigenicity. However, EV isolation from biofluids constitutes a major bottleneck in these applications largely due to the yield and purity limitations of the current technologies. This project aims to overcome these challenges by developing an aptamer-functionalized-magnetic-nanoparticle-based extraction kit with easy-to-follow protocols and ready-to-use reagents for isolating EVs from various types of biofluids, with high yield and purity, suitable for downstream EV molecular analysis. Successful completion of this project has a substantial economic impact on the biotech industry of Canada. The potential outcomes and impacts include: (1) one of the first EV isolation kits made in Canada with both established protocols and ready-to-use reagents; (2) enabling broader applications of EVs in health and life sciences; (3) enhancing the competitiveness of the Canadian biotechnology companies both at home and in the global market; (4) training of HQP in nano-biotechnology and EV science.